vs
Ametek（AME）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
Ametek的季度营收约是MESA LABORATORIES INC的30.7倍（$2.0B vs $65.1M）。Ametek净利率更高（19.9% vs 5.6%，领先14.4%）。Ametek同比增速更快（13.4% vs 3.6%）。Ametek自由现金流更多（$527.3M vs $18.0M）。过去两年Ametek的营收复合增速更高（7.3% vs 5.1%）
AMETEK Inc.是美国跨国综合企业，为全球知名的电子仪器及机电设备设计商与制造商，总部位于美国，在全球范围内设有超过150个运营站点，业务覆盖多个国家和地区，为各行业客户提供高性能的相关产品及配套解决方案。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
AME vs MLAB — 直观对比
营收规模更大
AME
是对方的30.7倍
$65.1M
营收增速更快
AME
高出9.8%
3.6%
净利率更高
AME
高出14.4%
5.6%
自由现金流更多
AME
多$509.2M
$18.0M
两年增速更快
AME
近两年复合增速
5.1%
损益表 — Q4 2025 vs Q3 2026
| 指标 | | |
|---|---|---|
| 营收 | $2.0B | $65.1M |
| 净利润 | $398.6M | $3.6M |
| 毛利率 | 36.0% | 64.2% |
| 营业利润率 | 25.3% | 12.2% |
| 净利率 | 19.9% | 5.6% |
| 营收同比 | 13.4% | 3.6% |
| 净利润同比 | 2.9% | 316.6% |
| 每股收益（稀释后） | $1.73 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMEMLAB
| Q4 25 | $2.0B | $65.1M | ||
| Q3 25 | $1.9B | $60.7M | ||
| Q2 25 | $1.8B | $59.5M | ||
| Q1 25 | $1.7B | $62.1M | ||
| Q4 24 | $1.8B | $62.8M | ||
| Q3 24 | $1.7B | $57.8M | ||
| Q2 24 | $1.7B | $58.2M | ||
| Q1 24 | $1.7B | $58.9M |
净利润AMEMLAB
| Q4 25 | $398.6M | $3.6M | ||
| Q3 25 | $371.4M | $2.5M | ||
| Q2 25 | $358.4M | $4.7M | ||
| Q1 25 | $351.8M | $-7.1M | ||
| Q4 24 | $387.3M | $-1.7M | ||
| Q3 24 | $340.2M | $3.4M | ||
| Q2 24 | $337.7M | $3.4M | ||
| Q1 24 | $310.9M | $-254.6M |
毛利率AMEMLAB
| Q4 25 | 36.0% | 64.2% | ||
| Q3 25 | 36.3% | 61.5% | ||
| Q2 25 | 35.8% | 62.0% | ||
| Q1 25 | 36.1% | 61.8% | ||
| Q4 24 | 36.6% | 63.3% | ||
| Q3 24 | 36.0% | 61.3% | ||
| Q2 24 | 36.0% | 64.0% | ||
| Q1 24 | 34.1% | 62.1% |
营业利润率AMEMLAB
| Q4 25 | 25.3% | 12.2% | ||
| Q3 25 | 25.8% | 7.8% | ||
| Q2 25 | 26.0% | 5.1% | ||
| Q1 25 | 26.3% | 2.4% | ||
| Q4 24 | 26.6% | 9.2% | ||
| Q3 24 | 26.1% | 6.1% | ||
| Q2 24 | 25.8% | 9.6% | ||
| Q1 24 | 24.0% | -460.6% |
净利率AMEMLAB
| Q4 25 | 19.9% | 5.6% | ||
| Q3 25 | 19.6% | 4.1% | ||
| Q2 25 | 20.2% | 8.0% | ||
| Q1 25 | 20.3% | -11.4% | ||
| Q4 24 | 22.0% | -2.7% | ||
| Q3 24 | 19.9% | 5.9% | ||
| Q2 24 | 19.5% | 5.8% | ||
| Q1 24 | 17.9% | -432.2% |
每股收益（稀释后）AMEMLAB
| Q4 25 | $1.73 | $0.65 | ||
| Q3 25 | $1.60 | $0.45 | ||
| Q2 25 | $1.55 | $0.85 | ||
| Q1 25 | $1.52 | $-1.30 | ||
| Q4 24 | $1.67 | $-0.31 | ||
| Q3 24 | $1.47 | $0.63 | ||
| Q2 24 | $1.45 | $0.62 | ||
| Q1 24 | $1.34 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $458.0M | $29.0M |
| 总债务越低越好 | $2.3B | $68.4M |
| 股东权益账面价值 | $10.6B | $186.7M |
| 总资产 | $16.1B | $434.8M |
| 负债/权益比越低杠杆越低 | 0.21× | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资AMEMLAB
| Q4 25 | $458.0M | $29.0M | ||
| Q3 25 | $439.2M | $20.4M | ||
| Q2 25 | $619.7M | $21.3M | ||
| Q1 25 | $399.0M | $27.3M | ||
| Q4 24 | $374.0M | $27.3M | ||
| Q3 24 | $396.3M | $24.3M | ||
| Q2 24 | $396.6M | $28.5M | ||
| Q1 24 | $373.8M | $28.2M |
总债务AMEMLAB
| Q4 25 | $2.3B | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | $2.1B | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益AMEMLAB
| Q4 25 | $10.6B | $186.7M | ||
| Q3 25 | $10.5B | $178.5M | ||
| Q2 25 | $10.4B | $172.5M | ||
| Q1 25 | $10.0B | $159.8M | ||
| Q4 24 | $9.7B | $155.2M | ||
| Q3 24 | $9.6B | $161.5M | ||
| Q2 24 | $9.3B | $150.7M | ||
| Q1 24 | $9.0B | $145.4M |
总资产AMEMLAB
| Q4 25 | $16.1B | $434.8M | ||
| Q3 25 | $16.2B | $430.4M | ||
| Q2 25 | $15.3B | $435.7M | ||
| Q1 25 | $14.9B | $433.3M | ||
| Q4 24 | $14.6B | $433.3M | ||
| Q3 24 | $14.8B | $454.1M | ||
| Q2 24 | $14.8B | $440.4M | ||
| Q1 24 | $14.9B | $446.8M |
负债/权益比AMEMLAB
| Q4 25 | 0.21× | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | 0.22× | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $584.3M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $527.3M | $18.0M |
| 自由现金流率自由现金流/营收 | 26.4% | 27.7% |
| 资本支出强度资本支出/营收 | 2.9% | 1.1% |
| 现金转化率经营现金流/净利润 | 1.47× | 5.17× |
| 过去12个月自由现金流最近4个季度 | $1.7B | $37.9M |
8季度趋势，按日历期对齐
经营现金流AMEMLAB
| Q4 25 | $584.3M | $18.8M | ||
| Q3 25 | $440.9M | $8.2M | ||
| Q2 25 | $359.1M | $1.9M | ||
| Q1 25 | $417.5M | $12.7M | ||
| Q4 24 | $550.0M | $18.1M | ||
| Q3 24 | $487.2M | $5.3M | ||
| Q2 24 | $381.4M | $10.7M | ||
| Q1 24 | $410.2M | $12.9M |
自由现金流AMEMLAB
| Q4 25 | $527.3M | $18.0M | ||
| Q3 25 | $420.0M | $7.1M | ||
| Q2 25 | $329.8M | $884.0K | ||
| Q1 25 | $394.5M | $11.9M | ||
| Q4 24 | $498.3M | $17.3M | ||
| Q3 24 | $460.9M | $3.5M | ||
| Q2 24 | $360.0M | $9.9M | ||
| Q1 24 | $382.6M | $12.3M |
自由现金流率AMEMLAB
| Q4 25 | 26.4% | 27.7% | ||
| Q3 25 | 22.2% | 11.7% | ||
| Q2 25 | 18.5% | 1.5% | ||
| Q1 25 | 22.8% | 19.2% | ||
| Q4 24 | 28.3% | 27.6% | ||
| Q3 24 | 27.0% | 6.0% | ||
| Q2 24 | 20.8% | 16.9% | ||
| Q1 24 | 22.0% | 21.0% |
资本支出强度AMEMLAB
| Q4 25 | 2.9% | 1.1% | ||
| Q3 25 | 1.1% | 1.8% | ||
| Q2 25 | 1.6% | 1.7% | ||
| Q1 25 | 1.3% | 1.2% | ||
| Q4 24 | 2.9% | 1.3% | ||
| Q3 24 | 1.5% | 3.1% | ||
| Q2 24 | 1.2% | 1.5% | ||
| Q1 24 | 1.6% | 0.9% |
现金转化率AMEMLAB
| Q4 25 | 1.47× | 5.17× | ||
| Q3 25 | 1.19× | 3.32× | ||
| Q2 25 | 1.00× | 0.40× | ||
| Q1 25 | 1.19× | — | ||
| Q4 24 | 1.42× | — | ||
| Q3 24 | 1.43× | 1.54× | ||
| Q2 24 | 1.13× | 3.17× | ||
| Q1 24 | 1.32× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AME
| Transferred At Point In Time | $1.1B | 54% |
| Electronic Instruments Group | $620.1M | 31% |
| Transferred Over Time | $294.6M | 15% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
